Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy Market

Duchenne Muscular Dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. The disease is caused by an absence of dystrophin, a protein that helps keep muscle cells intact.


DMD is caused by changes (mutations) in the DMD gene. The DMD gene codes for the protein dystrophin. Dystrophin is mainly made in skeletal and heart muscle cells, but a small amount is made in nerve cells (neurons) in specific parts of the brain. DMD is inherited in an X-linked recessive pattern and is passed on by the mother, referred to as a carrier; however, it may also occur in people who do not have a family history of DMD. 


Duchenne Muscular Dystrophy Epidemiological Segmentation 

The Epidemiological Segmentation of Duchenne Muscular Dystrophy in 7MM from 2017 to 2030 is segmented as:- 

  • Total Prevalent Cases
  • Total Diagnosed Prevalent Population of Non-ambulatory DMD 
  • Total Diagnosed Prevalent Population
  • Age-Specific Diagnosed Prevalence
  • Mutation-Specific Diagnosed Prevalence 
  • Prevalent Population Of Associated Comorbidities With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy Epidemiology 

  • The total diagnosed DMD prevalent population in the 7MM in 2017 was 27,685
  • The diagnosed prevalent cases of DMD patients in the United States in 2017 were 16,840


Duchenne Muscular Dystrophy Market

The Market Size of Duchenne Muscular Dystrophy in the 7MM in 2017 was USD 266.06 Million 


Duchenne Muscular Dystrophy Market Drivers

  • Robust Pipeline Activity
  • Upcoming Launches and Approval
  • Awareness

 

Duchenne Muscular Dystrophy Market Barriers

  • High Treatment Cost
  • Complicated chain for a multidisciplinary care
  • Disease management & treatment


Duchenne Muscular Dystrophy Emerging Drugs

The emerging drugs of the Duchenne Muscular Dystrophy market are 

  • Casimersen
  • Puldysa (Idebenone)
  • Givinostat
  • Edasalonexent
  • Viltolarsen
  • PF-06939926
  • TAS-205
  • Pamrevlumab (FG-3019)
  • DS-5141b

And many others. 


Duchenne Muscular Dystrophy Key Players

The key players in the Duchenne Muscular Dystrophy market are

  • Sarepta Therapeutics
  • Santhera Pharmaceuticals
  • Italfarmaco
  • Catabasis Pharmaceuticals
  • Nippon Shinyaku
  • Pfizer
  • Taiho Pharmaceutical
  • FibroGen
  • Daiichi Sankyo

  And many others.